Celcuity (CELC) Earnings Date & Reports

Key Takeaways

• Celcuity is scheduled to report Q2 2026 financial results in early August 2026, marking its first earnings release since securing FDA approval for REVTORPYK (gedatolisib) on July 14, 2026.
• Consensus analyst estimates for Q2 2026 point to an EPS (earnings per share) loss ranging from approximately -$1.11 to -$1.16, reflecting continued investment ahead of the anticipated commercial launch.
• Investors will closely monitor the company's cash position, operating expense trajectory, and any updates regarding the late-Q3 2026 commercial rollout of REVTORPYK.
• The stock has pulled back roughly 26% from its post-approval high near $111, reflecting questions around launch timing and near-term cash burn, despite a Strong Buy consensus from Wall Street analysts.
• Beyond the headline numbers, commentary on the supplemental New Drug Application (sNDA) for the PIK3CA-mutant indication and VIKTORIA-2 clinical trial progress will be key sentiment drivers.

Earnings Context and Why It Matters

Celcuity's Q2 2026 earnings report represents a pivotal moment for the Minneapolis-based biotechnology company. On July 14, 2026, the U.S. Food and Drug Administration (FDA) granted full approval to REVTORPYK for the treatment of HR-positive, HER2-negative, PIK3CA wild-type advanced or metastatic breast cancer — the company's first-ever commercial product. This transformative milestone shifted Celcuity from a clinical-stage enterprise to a fully integrated commercial-stage biotech. The Q2 report will be the first financial disclosure since that landmark event, making it a critical checkpoint for investors evaluating the company's pre-launch spending trajectory, balance sheet strength, and execution readiness. With a 100-person commercial sales organization already onboarded and a served market estimated at over $6 billion in the second-line setting, the stakes surrounding this earnings print are exceptionally high.

Earnings Expectations

Wall Street expects Celcuity to report another quarter of significant net losses as the company continues investing heavily in both its commercial infrastructure and clinical pipeline. The consensus EPS estimate for Q2 2026 ranges from approximately -$1.11 to -$1.16, depending on the data provider. This compares to a Q1 2026 reported EPS of -$0.97, which beat consensus by $0.10, and a Q2 2025 loss of -$1.04 per share. Revenue is expected to remain negligible, as REVTORPYK's commercial launch is not anticipated until late in the third quarter of 2026.

Key metrics investors will scrutinize include R&D (research and development) expenses, which totaled $33.1 million in Q1 2026, and SG&A (selling, general, and administrative) costs, which surged to $17.4 million in Q1 2026 — a nearly 176% year-over-year increase — reflecting the buildout of the commercial organization. Cash, cash equivalents, and short-term investments stood at $387.1 million as of March 31, 2026. Management previously indicated that existing cash, together with drawdowns on the company's debt facility, should fund operations through 2027, but updated runway guidance will be a focal point for analysts. Historically, CELC has beaten EPS estimates in three of the past four quarters.

AI Screener

For investors seeking to identify opportunities in the biotechnology sector or track companies approaching pivotal catalysts like Celcuity's commercial launch, Tickeron's AI Screener offers a powerful solution. This AI-driven stock and ETF discovery tool enables traders and investors to filter thousands of equities using customizable criteria such as industry classification, market capitalization, technical indicators, price patterns, volatility metrics, and AI-generated signals. Whether scanning for breakout candidates in oncology, pre-revenue biotechs approaching regulatory milestones, or stocks exhibiting specific chart patterns, the AI Screener streamlines the discovery process far more efficiently than manual screening. Explore how AI-powered filtering can help surface trade ideas and market opportunities tailored to your investment approach.

Market Reaction and Investor Sentiment

Market reaction to Celcuity's recent historic catalyst has been notably complex. Following the FDA approval on July 14, shares initially rallied to approximately $111 before reversing sharply — shedding nearly 18% the following day and continuing a gradual decline to trade around $82 as of late July 2026. The stock now sits roughly 26% below its post-approval high. The pullback appears driven by several factors: management's disclosure that commercial launch would occur "late in the third quarter" rather than immediately, the need to build sufficient drug inventory before launch, and ongoing cash burn concerns as operating expenses continue climbing ahead of meaningful revenue generation. Despite the selloff, analyst sentiment remains overwhelmingly positive, with all 12 covering analysts maintaining Buy or equivalent ratings and an average 12-month price target of approximately $163.45 — implying nearly 98% upside from current levels. Heading into Q2 earnings, investor sentiment is cautiously optimistic but acutely sensitive to any updates regarding launch timeline, pricing strategy, and cash runway.

Forward Outlook and Key Factors to Monitor

Looking beyond Q2 results, several catalysts and risk factors will shape Celcuity's trajectory through the remainder of 2026 and into 2027.

The most immediate and consequential event is the commercial launch of REVTORPYK, now expected in the late third quarter of 2026. Investors should pay close attention to any updates on drug supply readiness, pricing details (management has indicated a premium to existing therapies), and early indicators of physician and payer receptivity. The company's 100-person sales force, targeting approximately 9,000 healthcare providers and focusing on roughly 2,000 high-volume breast cancer specialists, will need to execute a successful rollout in a competitive landscape that includes established therapies from AstraZeneca, Novartis, and Eli Lilly.

Equally important is the planned sNDA submission in Q3 2026 seeking approval for REVTORPYK in PIK3CA-mutant patients. If approved, this label expansion would double the addressable patient population in the second-line setting, broadening the drug's commercial opportunity to what management estimates as a greater-than-$6 billion market.

On the clinical front, progress on the VIKTORIA-2 Phase III trial — evaluating REVTORPYK in the first-line setting — and the Phase Ib metastatic castration-resistant prostate cancer (mCRPC) study will remain important long-term value drivers. VIKTORIA-2 topline data is expected by the end of 2028, while prostate cancer data is anticipated in Q4 2026. Investors should also monitor expense discipline, as quarterly operating expenses now exceed $50 million, and any acceleration or deceleration in R&D or SG&A spending will directly impact cash runway projections through 2027.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations